All In Biotech

Drug Trial Radar · NCT05642507

Phase Ib/IIa Trial With AC01 in Patients With HFrEF

Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled, Safety, Tolerability, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Phase Ib/IIa Clinical Trial With AC01 in Patients With HFrEF

Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Feb 23, 2023

Primary completion

Oct 27, 2025

Study completion Oct 27, 2025

Sponsor

Lead sponsor
AnaCardio ABIndustry
Sponsor type
Industry
First posted
Dec 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in patients with heart failure with reduced ejection fraction (HFrEF).

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

  • AC01Drug

    AC01 Minitablets

  • Placebo MinitabletsDrug

    Placebo Minitablets are indistinguishable from active AC01 Minitablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability: Adverse Events (AEs)Time frame: From first dose of study drug up to end of follow up (up to 12 days during dose escalation phase and up to 35 days during cohort expansion phase).
  2. Safety and tolerability: Vital signs.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion)
  3. Safety and tolerability: Vital signs.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
  4. Safety and tolerability: Vital signs.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
  5. Safety and tolerability: Electrocardiogram (ECG).Time frame: From first dose of study drug up to end of follow up (up to 12 days during dose escalation phase and up to 35 days during cohort expansion phase).
  6. Safety and tolerability: Electrocardiogram (ECG).Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
  7. Safety and tolerability: Clinical laboratory evaluations.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
  8. Safety and tolerability: Clinical laboratory evaluations.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
  9. Safety and tolerability: Clinical laboratory evaluations.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).

Locations

14 sites in 4 countries. Site status is shown where the registry gives one.

  • Spedali Civilia di Brescia

    Brescia, Italy

  • Azienda Sanitaria Universitaria Integrata

    Trieste, Italy

  • Amsterdam University Medical Centre

    Amsterdam, Netherlands

  • University Medical Centre Groningen/ICON

    Groningen, Netherlands

  • Maastricht Heart and Vascular Center

    Maastricht, Netherlands

  • Erasmus Medical Centre

    Rotterdam, Netherlands

  • University Medical Center

    Utrecht, Netherlands

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • Skånes Universitetssjukhus Lund

    Lund, Sweden

  • Karolinska University Hospital

    Stockholm, Sweden

  • Ninewells Hospital and Medical School

    Dundee, United Kingdom

  • University of Glasgow, Institute of Cardiovascular & Medical Sciences

    Glasgow, United Kingdom

  • Golden Jubilee National Hospital

    Glasgow, United Kingdom

  • King's College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.